Literature DB >> 26649644

Non-canonical Stat3 signaling in cancer.

Jaya Srivastava1, John DiGiovanni1.   

Abstract

Stat3 is a member of the signal transducers and activators of transcription family and is a known regulator of essential biologic processes including angiogenesis, apoptosis, cell cycle progression, and cell migration. Canonical Stat3-mediated signaling involves tyrosine phosphorylation on specific residues that leads to homodimerization and translocation to the nucleus. For many years it was presumed that most, if not all, of the functions of Stat3, both normal and aberrant, were due to the canonical cytokine and growth factor signaling mechanisms. Recent studies suggest that Stat3 functions through alternate non-canonical pathways to bring about some of these biological functions both in normal cells as well as during cancer development and progression. A number of studies have now shown that Stat3 has a function in mitochondria and that unphosphorylated Stat3 (uStat3) can also function as a transcription factor broadening the potential mechanisms involved in Stat3 action. In this review article, we discuss these two main non-canonical functions of Stat3 and their potential roles in oncogenesis. Given the many facets of Stat3 signaling, additional comprehensive investigations are required to fully understand the role of non-canonical Stat3 signaling in cancer and whether these pathways can be targeted for cancer prevention and treatment.
© 2015 Wiley Periodicals, Inc. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  Stat3; cancer; mitostat3; non-canonical; ustat3

Mesh:

Substances:

Year:  2015        PMID: 26649644     DOI: 10.1002/mc.22438

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  21 in total

1.  ApoC1 promotes the metastasis of clear cell renal cell carcinoma via activation of STAT3.

Authors:  Yang-Ling Li; Lin-Wen Wu; Ling-Hui Zeng; Zuo-Yan Zhang; Wei Wang; Chong Zhang; Neng-Ming Lin
Journal:  Oncogene       Date:  2020-08-21       Impact factor: 9.867

2.  Suppression of STAT3 NH2 -terminal domain chemosensitizes medulloblastoma cells by activation of protein inhibitor of activated STAT3 via de-repression by microRNA-21.

Authors:  Sutapa Ray; Don W Coulter; Shawn D Gray; Jason A Sughroue; Shrabasti Roychoudhury; Erin M McIntyre; Nagendra K Chaturvedi; Kishor K Bhakat; Shantaram S Joshi; Timothy R McGuire; John G Sharp
Journal:  Mol Carcinog       Date:  2018-01-25       Impact factor: 4.784

3.  Ropivacaine Induces Cell Cycle Arrest in the G0/G1 Phase and Apoptosis of PC12 Cells via Inhibiting Mitochondrial STAT3 Translocation.

Authors:  Lian Zeng; Aohan Li; Zhen Zhang; Fuyu Zhang; Huaxian Chen; Ying Wang; Xudong Ding; Huiyu Luo
Journal:  Inflammation       Date:  2021-08-20       Impact factor: 4.092

4.  STAT3 mediates RCP-induced cancer cell invasion through the NF-κB/Slug/MT1-MMP signaling cascade.

Authors:  Su Jin Cho; Bo Young Jeong; Young Soo Song; Chang Gyo Park; Do Yeun Cho; Hoi Young Lee
Journal:  Arch Pharm Res       Date:  2022-07-09       Impact factor: 6.010

Review 5.  Molecular signaling cascades involved in nonmelanoma skin carcinogenesis.

Authors:  Robert P Feehan; Lisa M Shantz
Journal:  Biochem J       Date:  2016-10-01       Impact factor: 3.857

6.  A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo.

Authors:  Longchuan Bai; Haibin Zhou; Renqi Xu; Yujun Zhao; Krishnapriya Chinnaswamy; Donna McEachern; Jianyong Chen; Chao-Yie Yang; Zhaomin Liu; Mi Wang; Liu Liu; Hui Jiang; Bo Wen; Praveen Kumar; Jennifer L Meagher; Duxin Sun; Jeanne A Stuckey; Shaomeng Wang
Journal:  Cancer Cell       Date:  2019-11-11       Impact factor: 31.743

7.  BRD4 Regulates Transcription Factor ΔNp63α to Drive a Cancer Stem Cell Phenotype in Squamous Cell Carcinomas.

Authors:  Matthew L Fisher; Seamus Balinth; Yon Hwangbo; Caizhi Wu; Carlos Ballon; John E Wilkinson; Gary L Goldberg; Alea A Mills
Journal:  Cancer Res       Date:  2021-10-25       Impact factor: 13.312

8.  Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts.

Authors:  Keren B Turton; Stephane Esnault; Larissa P Delain; Deane F Mosher
Journal:  J Vis Exp       Date:  2016-10-09       Impact factor: 1.355

9.  Analysis of STAT3 post-translational modifications (PTMs) in human prostate cancer with different Gleason Score.

Authors:  Rossana Cocchiola; Donatella Romaniello; Caterina Grillo; Fabio Altieri; Marcello Liberti; Fabio Massimo Magliocca; Silvia Chichiarelli; Ilaria Marrocco; Giuseppe Borgoni; Giacomo Perugia; Margherita Eufemi
Journal:  Oncotarget       Date:  2017-06-27

Review 10.  Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides.

Authors:  Jamie V Shiah; Jennifer R Grandis; Daniel E Johnson
Journal:  Mol Cancer Ther       Date:  2020-11-17       Impact factor: 6.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.